Peptides for facial aesthetics: what the evidence actually says

What did @de3xpilled actually say?

The creator called semax and selank "coke peptides" — a slang term implying they're overhyped stimulants with no real payoff. They tried both for what they describe as a "prescribed time" using seven-day cycles and reported feeling "absolutely nothing" from semax and "no difference" from selank. Their conclusion: skip both and just use modafinil or Adderall if you want cognitive enhancement. That's the whole argument. Personal experience plus a drug recommendation, no mechanism discussed, no dosing context, no literature cited.

To be clear about the terminology: "coke peptide" appears to be creator slang for overhyped nootropic compounds, not a pharmacological classification. Semax is a synthetic analogue of ACTH(4-7) originally developed in Russia. Selank is a heptapeptide derived from tuftsin, also developed in Russia, with proposed anxiolytic and nootropic properties. Neither is FDA-approved in the United States.

Does the science back this up?

The honest answer is: the clinical evidence for both compounds is thin, inconsistent, and mostly from Russian sources with limited independent replication. That doesn't mean they do nothing, but it does mean @de3xpilled's dismissal isn't unreasonable as a consumer experience.

Semax has been studied for cognitive enhancement and neuroprotection. A 2014 study by Lebedeva et al. in the journal Bulletin of Experimental Biology and Medicine found semax increased BDNF levels in rat models, which sounds impressive until you remember rats are not humans and BDNF elevation doesn't automatically translate to subjective cognitive improvement. Human trials are sparse and primarily from Russian clinical settings with small sample sizes and methodological questions. Selank has similarly thin Western evidence. A 2014 paper by Zozulya et al. in CNS Drug Reviews reviewed selank's anxiolytic properties and found promising signals, but again the research base is narrow. The creator's subjective non-response is not proof the peptides don't work, but it's also not surprising given how variable the evidence is.

What did they get wrong (or right)?

They got the skepticism directionally right. Calling these compounds overhyped is defensible. Where they went wrong is the leap to recommending modafinil or Adderall as substitutes.

Modafinil and Adderall are Schedule IV and Schedule II controlled substances respectively. Adderall is an amphetamine. Recommending either as a casual swap for peptides you didn't personally respond to is irresponsible and pharmacologically sloppy. Adderall carries real cardiovascular risks, dependence potential, and is not approved for general cognitive enhancement in healthy adults. Modafinil is better tolerated but still a prescription drug with its own side effect profile. Telling 21,500 viewers to "just use" either of these because a peptide didn't work for you personally is the kind of advice that belongs nowhere near a health platform.

The seven-day cycle claim also deserves scrutiny. Semax protocols in the literature vary considerably. A user's self-reported non-response after one cycle, with no mention of dose, route of administration, or baseline cognitive testing, tells us essentially nothing about the compound's efficacy.

What should you actually know?

Semax and selank are not FDA-approved. They exist in a regulatory gray zone in the US, often sold as research chemicals. If you've seen them promoted heavily in peptide communities, that's real, and the hype does outrun the evidence. But "I felt nothing" from one person over one unspecified cycle is not a clinical verdict.

Both compounds have proposed mechanisms worth taking seriously on paper. Semax's BDNF-related activity and selank's GABAergic and enkephalin-modulating effects are biologically plausible. The problem is plausibility is not efficacy, and neither compound has robust randomized controlled trial data in healthy humans showing meaningful cognitive improvement. If you're considering either for cognitive or anxiety-related purposes, that conversation belongs with a licensed clinician who can assess your baseline, not a TikTok comment section.

And if a creator's primary takeaway is to swap to a Schedule II amphetamine because a research peptide didn't hit, that's a red flag worth noting.